** Shares of biotech firm TG Therapeutics TGTX.O rise 2.7% to $28.51 premarket

**  Presented new findings on multiple sclerosis therapy Briumvi for treating a relapsing type of the nerve disorder

** Multiple sclerosis is an autoimmune nerve disorder where the immune system attacks the protective coating around nerves, disrupting signals between the brain and body

** Updates include real‑world data and studies in children and teens

**  Most common side effects were infusion reactions and respiratory infections; serious infections seen in 5% of patients

** Shares ended marginally lower in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))